Novartis resumes remote business in Ukraine after safety protocol review
Months after a slate of pharma companies slammed the brakes on some operations in both Russia and Ukraine, Novartis announced that it’s resuming business remotely in Ukraine “to help the war-torn country restore some basic critical business processes.”
Novartis came to the decision after studying safety protocols and receiving advice “which we will regularly review,” the company said on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.